- Khiron to launch two additional small-format Zerenia™ clinics
in major metropolitan centres outside of Bogota in early March
2021, following successful launch of the Company's first
small-format clinic in Medellin in
December 2020
- New clinics bring Khiron's total number of clinics in
Colombia to six, expanding
regional access throughout the country, where an estimated 6
million people have conditions that may be treated with medical
cannabis (Source: IMS Quintiles)
- In January, eight of every ten patients obtained a paid
prescription at the initial Medellin small-format clinic
- Small-format clinics leverage the Company's substantial
investment in technology, best practices, brand development, and
physician training and internship programs, in country of 50
million people
- With low capital costs, direct-to-patient sales, and medical
cannabis insurance coverage, small-format clinics can generate a
high return on investment, as well as high patient retention
rates
TORONTO, Feb. 10, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, today announces that it will launch
two additional small-format Zerenia™ clinics in Q1 2021. The new
clinics, which follow on the successful launch of the Company's
first small-format clinic in Medellin, will be located in high-traffic,
medical-hub neighbourhoods in two of Colombia's largest metropolitan centres
outside of Bogota.
The two new small-format Zerenia™ clinics, which are expected to
open in early March, will expand Khiron's network to six clinics,
improving regional access to the Company's clinic services and
medical cannabis products for patients across the country.
"Since opening our first small-format Zerenia™ clinic in
Medellin in December 2020, we have seen tremendous patient
demand for our products and services. Patient consultations and
prescriptions continue to accelerate, with eight of every ten
patients now receiving a paid prescription, despite operating in
pandemic conditions. Having proven the demand for local physicians
and the robust economics associated with small-format clinics,
Khiron will continue to expand its regional presence, in
Colombia and beyond," comments
Alvaro Torres, Khiron CEO and
Director.
Supported by Khiron's larger clinics licences, the two new
Zerenia™ small-format clinics will provide consultations both in
person and through the Doctor Zerenia™ telemedicine platform,
connecting patients with medical specialists trained in the
ethical, safe, and responsible prescription of cannabis-based
medications. Medical cannabis continues to be validated as an
effective treatment of pathologies such as chronic pain, anxiety,
insomnia, depression, headache, epilepsy, and Parkinson's
Disease.
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading medical cannabis provider in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Colombia, Peru and the UK, and is positioned to commence
sales of medical cannabis in Germany and Brazil in early 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing unit launched the
first branded CBD skincare brand in Colombia, with KuidaTM now marketed
in multiple jurisdictions in Latin
America, the US and UK. The Company is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced and diverse executive
team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-announces-expansion-of-small-format-zerenia-clinics-in-colombia-following-success-of-initial-launch-301225631.html
SOURCE Khiron Life Sciences Corp.